Novel Translational Pharmacology Approaches On Dose Reduction And Alternative Scheduling For The Combination Of Jak Inhibitor, Ruxolitinib, Pim Inhibitor, Lgh447, And Cdk4/6 Inhibitor, Lee011 In A Preclinical Model Of Myeloproliferative Neoplasia